Betulinic Acid

Betulinic Acid

SCHEMBL21264235

C=C(C)C1CC[C@]2(C(=O)O)CC[C@]3(C)[C@H](CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@]43C)[C@@H]12

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RORC P51449 4/20 1.00
PTPN1 P18031 3/20 1.00
GPBAR1 Q8TDU6 3/20 1.00
ALB P02768 3/20 1.00
GLI1 P08151 2/20 1.00
USP2 O75604 2/20 1.00
LMNA P02545 2/20 1.00
HIF1A Q16665 2/20 1.00
AKR1B10 O60218 1/20 1.00
POLB P06746 1/20 1.00
AKR1B1 P15121 1/20 1.00
NT5E P21589 1/20 1.00
DPP4 P27487 1/20 1.00
SAE1 Q9UBE0 1/20 1.00
UBA2 Q9UBT2 1/20 1.00
EGLN2 Q96KS0 1/20 0.82
EGLN1 Q9GZT9 1/20 0.82
EGLN3 Q9H6Z9 1/20 0.82
P4HTM Q9NXG6 1/20 0.82
CES2 O00748 2/20 0.80

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Betulinic Acid SCHEMBL14112364 1.00 RORC (1.00) RORCPTPN1GPBAR1ALBGLI1
Betulinic Acid SCHEMBL13908717 1.00 RORC (1.00) RORCPTPN1GPBAR1ALBGLI1
Betulinic Acid SCHEMBL14112012 1.00 RORC (1.00) RORCPTPN1GPBAR1ALBGLI1
Betulinic Acid SCHEMBL7746410 1.00 RORC (1.00) RORCPTPN1GPBAR1ALBGLI1
Betulinic Acid SCHEMBL10214465 1.00 RORC (1.00) RORCPTPN1GPBAR1ALBGLI1
Betulinic Acid SCHEMBL9905925 1.00 RORC (1.00) RORCPTPN1GPBAR1ALBGLI1
Betulinic Acid SCHEMBL23132693 1.00 RORC (1.00) RORCPTPN1GPBAR1ALBGLI1
Betulinic Acid SCHEMBL13285621 1.00 RORC (1.00) RORCPTPN1GPBAR1ALBGLI1
Betulinic Acid SCHEMBL22251646 1.00 RORC (1.00) RORCPTPN1GPBAR1ALBGLI1
Betulinic Acid SCHEMBL8283294 1.00 RORC (1.00) RORCPTPN1GPBAR1ALBGLI1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11660306-B2 Treatment of Rett syndrome COLD SPRING HARBOR LABORATORY (US) 2023-05-30 US disclosed
US-11660306-B2 Treatment of Rett syndrome COLD SPRING HARBOR LABORATORY (US) 2023-05-30 US disclosed
US-11007269-B2 P53 degradation inducing molecule and pharmaceutical composition TOKYO UNIVERSITY OF SCIENCE FOUNDATION (JP) 2021-05-18 US disclosed
US-20200109163-A1 CARBONATED BEVERAGE AND METHOD FOR CARBONATION ENHANCEMENT INTERNATIONAL FLAVORS & FRAGRANCES INC. 2020-04-09 US disclosed
US-20190314508-A1 P53 DEGRADATION INDUCING MOLECULE AND PHARMACEUTICAL COMPOSITION TOKYO UNIVERSITY OF SCIENCE FOUNDATION (JP) 2019-10-17 US disclosed
US-20190247408-A1 TREATMENT OF RETT SYNDROME COLD SPRING HARBOR LABORATORY (US) 2019-08-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190314508-A1 P53 DEGRADATION INDUCING MOLECULE AND PHARMACEUTICAL COMPOSITION TP53, TP53BP1, MDM2 RORC 2948/4885PTPN1 1561/4885GPBAR1 3266/4885
US-20200109163-A1 CARBONATED BEVERAGE AND METHOD FOR CARBONATION ENHANCEMENT CA9, CA2, CA4 RORC 3514/4885PTPN1 4828/4885GPBAR1 1674/4885
US-20190247408-A1 TREATMENT OF RETT SYNDROME MECP2, BDNF, NTRK2 RORC 1467/4885PTPN1 4223/4885GPBAR1 1534/4885
US-11660306-B2 Treatment of Rett syndrome MECP2, BDNF, NTRK2 RORC 1467/4885PTPN1 4223/4885GPBAR1 1534/4885
US-11007269-B2 P53 degradation inducing molecule and pharmaceutical composition TP53, TP53BP1, MDM2 RORC 2948/4885PTPN1 1561/4885GPBAR1 3266/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.